September 6, 2016

Centers for Medicare & Medicaid Services
Department of Health and Human Services
Attn: CMS-1654-P
P.O. Box 8013
Baltimore, MD 21244-8013

via electronic submission

RE: CMS-1654-P

Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY2017.

II. Provisions of the Proposed Rule for PFS, E. Improving Payment Accuracy for Primary Care, Care Management, and Patient-Centered Services, 5. Assessment and Care Planning for Patients With Cognitive Impairment

We write to express our strong support for the Centers for Medicare and Medicaid Services (CMS) proposed 2017 Physician Fee Schedule (PFS) Section II. E. 5. (Assessment and Care Planning for Patients With Cognitive Impairment), which recognizes the value of assessment and care planning services for patients with cognitive impairment, including people living with Alzheimer’s disease and other forms of dementia. The proposed rule would help improve quality of life for people living with dementia, support family caregivers, and reduce costs to federal and state health programs.

Clinical assessment and subsequent care planning services have long been a desire of the dementia advocacy community, as exemplified most clearly in longstanding pending legislation known as the Health Outcomes Planning and Education (HOPE) for Alzheimer’s Act. LEAD Coalition member organizations and other allies have advocated consistently on behalf of the HOPE Act, and are pleased that the Senate incorporated this policy within its draft Fiscal Year 2017 Labor, Health and Human Services and Education Appropriations Act.

The PFS proposed rule will complement numerous federal and state legislative initiatives, and ongoing public and private sector work to transform clinical practice. The ability of people living with dementia to enjoy a higher quality of life at home for longer periods of time will be advanced by these policy and practice changes to facilitate more timely and accurate
diagnosis along with earlier and more effective support in navigating the care-planning continuum.

We support CMS’s plan to establish a G Code for assessment and care planning. We understand a G Code to be temporary for the purposes of gathering data on beneficiary utilization and that the code would become permanent as soon as 2018. We support the proposed service elements, particularly “identification of caregiver(s), caregiver knowledge, caregiver needs, social supports, and the willingness of caregiver to take on caregiving tasks.”

The proposed rule and G Code address dementia in all its forms including Alzheimer’s disease, vascular disease, Lewy body dementia, frontotemporal degeneration, and mixed etiologies. Equally important is the recognition that a one-size-fits all approach to care and quality of life must become more tailored and responsive to the heterogeneity of people facing dementia including: women, people in medically under-served areas or ethnically and culturally diverse communities, those with intellectual and developmental disabilities, or with younger-onset disease.

We all know the public health, budgetary and macro-economic statistics about dementia. All too many people know first-hand the individual human toll. By creating the reimbursement and payment infrastructure necessary to support providers in working with beneficiaries and family members on comprehensive care planning, CMS can help overcome false and damaging assumptions that clinicians’ only purpose is to prescribe and that diagnosis is futile or harmful in the absence of available disease modifying therapeutic agents. This is a time of great and deserved hope as Congress and the National Institutes of Health have begun to address chronic underfunding of research aiming for scientific breakthroughs to prevent or stop dementia in its tracks by 2025. People living with dementia want breakthroughs and many participate in clinical trails to advance the science. But people living with dementia today cannot rest all their hopes in what science will produce in the coming years. They need what the proposed rule and G Code can deliver now: hope for the future and improved quality of life today.

We support the CMS analysis that services to be provided under this new G Code are not covered presently by existing codes. None of the existing codes appropriately reimburse providers for the necessary full extent of care planning services. Such services extend far beyond coordinating or managing the beneficiary’s care and would include guidance and direction that beneficiaries and their caregivers can follow to address current and future care needs.

As the final rule is developed, we urge CMS to recognize the progressive and debilitating nature of dementia to ensure that informal caregivers are included fully in such care planning sessions; in more advanced stages of dementia, it may not be possible to have the beneficiary directly involved in such discussions. In such cases, CMS should ensure that the care planning services still are transferred, as appropriate, to the beneficiary’s informal caregivers.

Thank you for considering our views and for your commitment to better supporting people with dementia by making this new code permanent by 2018. Please contact Ian Kremer, executive director of Leaders Engaged on Alzheimer's Disease (the LEAD Coalition), at ikremer@leadcoalition.org or (571) 383-9916, with questions or for additional information.
Sincerely,

Abe’s Garden
ACT on Alzheimer’s
Activists Against Alzheimer’s
African American Network Against Alzheimer’s
Ageless Alliance
AgeneBio
Paul S. Aisen, MD (Keck School of Medicine of USC, Alzheimer’s Therapeutic Research Institute*)
Allergan
Alzheimer’s & Dementia Alliance of Wisconsin
Alzheimer’s Drug Discovery Foundation
Alzheimer’s Foundation of America
Alzheimer’s Greater Los Angeles
Alzheimer’s Orange County
Alzheimer’s San Diego
Alzheimer’s Tennessee
AMDA – The Society for Post-Acute and Long-Term Care Medicine
American Academy of Neurology
American Association for Geriatric Psychiatry
American Federation for Aging Research
ARGENTUM | Expanding Senior Living
American Geriatrics Society
Laura D. Baker, PhD (Wake Forest School of Medicine*)
Banner Alzheimer’s Institute
David M. Bass, PhD (Benjamin Rose Institute on Aging*)
Beating Alzheimer’s by Embracing Science
Benjamin Rose Institute on Aging
Biogen
B’nai B’rith International
Soo Borson MD (University of Washington Schools of Medicine and Nursing*)
BrightFocus Alzheimer’s Disease Research
Brookdale Senior Living Inc.
Christopher M. Callahan, MD (Indiana University Center for Aging Research*)
Caregiver Action Network
CaringKind
Center for BrainHealth at The University of Texas at Dallas
Center for Elder Care and Advanced Illness, Altarum Institute
Center to Advance Palliative Care
Sandra Bond Chapman, PhD (Center for BrainHealth at The University of Texas at Dallas*)
Clergy Against Alzheimer’s
Cleveland Clinic Foundation
CorTechs Labs
Suzanne Craft, PhD (Wake Forest School of Medicine*)
Critical Path Institute/Coalition Against Major Diseases
Jeffrey Cummings, MD, ScD (Cleveland Clinic Lou Ruvo Center for Brain Health*)
Darrell K. Royal Fund for Alzheimer’s Research
Dementia Alliance International
Dementia Friendly America
Department of Neurology, Washington University School of Medicine
Rachelle S. Doody, MD, PhD (Baylor College of Medicine*)
Eli Lilly and Company
Gary Epstein-Lubow, MD (Alpert Medical School of Brown University*)
Sam Gandy, MD, PhD (Icahn School of Medicine at Mount Sinai*)
Joseph E. Gaugler, Ph.D. (School of Nursing, Center on Aging, University of Minnesota*)
General Electric Healthcare
Georgetown University Medical Center Memory Disorders Program
Georgia Institute on Aging
Gerontological Society of America
Laura N. Gitlin, PhD (Johns Hopkins School of Medicine*)
Lisa P. Gwyther, MSW, LCSW (Duke University Medical Center*)
David Holtzman, MD (Washington University School of Medicine, Department of Neurology*)
Huffington Center on Aging
Indiana University Center for Aging Research
Janssen R&D
Kathy Jedrziewski, PhD (University of Pennsylvania*)
Johns Hopkins Memory and Alzheimer's Treatment Center
Johns Hopkins School of Nursing Center for Innovative Care in Aging
Katherine S. Judge, PhD (Cleveland State University*)
Keck School of Medicine of USC, Alzheimer's Therapeutic Research Institute
Keep Memory Alive
Diana R Kerwin, MD (Texas Alzheimer's and Memory Disorders*)
Walter A. Kukull, PhD (School of Public Health, University of Washington*)
LatinosAgainstAlzheimer's
LeadingAge
Lewy Body Dementia Association
Linked Senior, Inc.
LuMind Research Down Syndrome Foundation
Lundbeck
Lutheran Services of America
Kostas Lyketsos, M.D., M.H.S. (Johns Hopkins Memory and Alzheimer's Treatment Center*)
David G. Morgan, PhD (USF Health Byrd Alzheimer's Institute*)
Mount Sinai Center for Cognitive Health
National Alliance for Caregiving
National Asian Pacific Center on Aging
National Association of Activity Professionals
National Association of Chronic Disease Directors
National Association of Nutrition and Aging Services Programs
National Association of Social Workers (NASW)
National Committee to Preserve Social Security and Medicare
National Council for Behavioral Health
National Down Syndrome Society
National Hispanic Council On Aging (NHCOC)
National Task Group on Intellectual Disabilities and Dementia Practices
Neurocern
Neurotechnology Industry Organization
NFL Neurological Center
NYU Alzheimer's Disease Center
NYU Langone Center on Cognitive Neurology
NYU Langone Medical Center
Noah Homes
OWL-The Voice of Women 40+
Pat Summitt Foundation
Piramal Imaging S.A.
Planetree
Presence Care Project
Prevent Alzheimer’s Disease 2020
Peter Reed, PhD (Sanford Center for Aging, University of Nevada Reno*)
Eric Reiman, MD (Banner Alzheimer’s Institute*)
ResearchersAgainstAlzheimer’s
Stephen Salloway, M.D., M.S. (The Warren Alpert Medical School of Brown University*)
Second Wind Dreams, Inc./Virtual Dementia Tour
Rudolph Tanzi, PhD (Department of Neurology, MGH/Harvard Medical School*)
The Association for Frontotemporal Degeneration
The Eden Alternative
The Youth Movement Against Alzheimer’s
Geoffrey Tremont, Ph.D., ABPP-CN (Alpert Medical School of Brown University*)
R. Scott Turner, MD, PhD (Georgetown University Memory Disorders Program*)
UsAgainstAlzheimer’s, LEAD Coalition co-convener
USF Health Byrd Alzheimer’s Institute
Volunteers of America, LEAD Coalition co-convener
Peter J. Whitehouse, MD, PhD (Case Western Reserve University*)
Nancy Wilson, MA LCSW (Baylor College of Medicine*)
WomenAgainstAlzheimer’s

* Affiliations of individual researchers are for identification purposes only and do not necessarily represent the endorsement of the affiliated institution.

http://www.leadcoalition.org Leaders Engaged on Alzheimer’s Disease (the LEAD Coalition) is a diverse national coalition of member organizations including patient advocacy and voluntary health non-profits, philanthropies and foundations, trade and professional associations, academic research and clinical institutions, and home and residential care providers, and biotechnology and pharmaceutical companies. The LEAD Coalition works collaboratively to focus the nation’s strategic attention on dementia in all its forms -- including Alzheimer’s disease, vascular disease, Lewy body dementia, and frontotemporal degeneration -- and to accelerate transformational progress in detection and diagnosis, care and support, and research leading to prevention, effective treatment and eventual cure. One or more participants may have a financial interest in the subjects addressed.